The suprachoroidal space (SCS) is a prospective pathway for novel drug delivery systems to treat posterior segment eye diseases, including uveitic macular edema. Listen to Drs. Srivastava and Sharma discuss tips on accessing the SCS and how these injections are being explored in several other posterior segment eye diseases.
This activity is supported by an unrestricted educational grant from Bausch + Lomb.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education 
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Sunil K. Srivastava, MD
Surgical Retina Fellowship Director
Cleveland Clinic Cole Eye Institute
Cleveland, OH
Sumit Sharma, MD
Assistant Professor, Ophthalmology
Cleveland Clinic
Lerner College of Medicine
Case Western Reserve University Staff
in Vitreoretinal Surgery and Uveitis
Cleveland Clinic Cole Eye Institute
Cleveland, OH
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Sunil K. Srivastava, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotechnologies, Bausch + Lomb, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Eyevensys, and Novartis. Grant/Research Support: Bausch + Lomb, EyePoint Pharmaceuticals, Eyevensys, and Regeneron.
Sumit Sharma, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Bausch + Lomb, Clearside, EyePoint Pharmaceuticals, Genentech, Regeneron, and RegenxBio. Grant/Research Support: Genentech, Gilead Sciences, Ionis, and Santen.
The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch + Lomb.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Christina Y. Weng, MD, MBA, FASRS
Katherine E. Talcott, MD
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
